Sipuleucel-T for prostate cancer: The immunotherapy era has commenced

Expert Review of Anticancer Therapy

Volumn 11, Issue 1, 2011, Pages 25-28

  Buonerba, Carlo ^a   Ferro, Matteo ^a   Lorenzo, Giuseppe Di ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

castration resistant setting; immunotherapy; PAP; prostate cancer; prostatic acid phosphatase; Prostvac VF; PSA; sipuleucel T

Indexed keywords

BEVACIZUMAB; BIOLOGICAL PRODUCT; CYTOTOXIC AGENT; DOCETAXEL; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYBRID PROTEIN; PLACEBO; PROSTATE SPECIFIC ANTIGEN; PROSTVAC VF; PROTEIN PA2024; PROVENGE; UNCLASSIFIED DRUG;

ANTIBODY TITER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHILL; CLINICAL PRACTICE; DRUG FEVER; DRUG INDUCED HEADACHE; HUMAN; LYMPHOCYTE PROLIFERATION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROSTATE ADENOCARCINOMA; PROSTATE CANCER; REVIEW; SOLID TUMOR; VIRUS GENOME;

CANCER VACCINES; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; MALE; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TISSUE EXTRACTS;

EID: 78650461231     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.10.180     Document Type: Review

References (9)

1. Kantoff PW, Higano CS, Shore ND et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363, 411-422 (2010).
2. Harzstark AL, Small EJ. Immunotherapeutics in development for prostate cancer. Oncologist 14, 391-398 (2009).
3. Small EJ, Schellhammer PF, Higano CS et al. Placebo-controlled Phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J. Clin. Oncol. 24, 3089-3094 (2006).
4. Kantoff PW, Schuetz TJ, Blumenstein BA et al. Overall survival analysis of a Phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J. Clin. Oncol. 28, 1099-1105 (2010).
5. Di Lorenzo G, Buonerba C, Faiella A et al. Phase II study of docetaxel re-treatment in docetaxel-pretreated castration-resistant prostate cancer. BJU Int. DOI: 10.1111/j.1464-410X.2010.09498.x (2010) (Epub ahead of print).
6. Buonerba C, Palmieri G, Di Lorenzo G. Docetaxel rechallenge in castration-resistant prostate cancer: scientific legitimacy of common clinical practice. Eur. Urol. 58, 636-637 (2010).
7. Di Lorenzo G, Buonerba C, Autorino R, De Placido S, Sternberg CN. Castration-resistant prostate cancer: current and emerging treatment strategies. Drugs 70, 983-1000 (2010).
8. Rini BI, Weinberg V, Fong L et al. Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (Provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy. Cancer 1, 67-74 (2006).
9. Longo DL. New therapies for castration-resistant prostate cancer. N. Engl. J. Med. 363, 479-481 (2010).